Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
08 June 2022 | Story Rulanzen Martin | Photo Pexels
Protest
Student protest has been a hot topic on many campuses across the country.

The University of the Free State (UFS) Faculty of the Humanities provided the platform for a robust dialogue on student protests in South Africa. The round-table discussion, titled ‘Humanistic Perspectives on Student Protests in South Africa’, took place on 30 May 2022, with an impressive panel drawn from the Humanities, senior management of the UFS, and student governance.  

Vice-Dean of the Faculty of the Humanities Prof Chitja Twala said the faculty thought it prudent to lead this discussion by hosting a round-table talk. “Student protest will be with us for some time, and we need to engage and talk about these issues from a humanistic point of view – it is important for us,” he said.

“It is only when we dialogue and engage with each other that we can meet each other halfway and understand the problems students are faced with, and students can understand the problems institutions of higher learning are faced with.”  

The dialogue was an opportunity to discuss humanistic perspectives on student protests and included the following topics, among others: dynamics of student protests, the relationship between politics and protests, why protests are a challenge for the higher education sector, and the possible responses to protests by universities. 

“We wanted an academic experience and we wanted to give a sense of the different kind of angles when looking at protest, and we have not even scratched the surface,” said Prof Heidi Hudson, Dean of the Faculty of the Humanities. 

* Listen to the discussion on the podcast recording below to gain insights from the six speakers. 


Protesting is important in addressing issues

Panellist Prof Sethulego Matebesi, who is an expert on community protests, said protesting is the main modality of expression for social movements in South Africa. He also said that protesting is a key element to celebrate, because people now have the right to protest. 

Student Governance Manager Motlogeloa Moema agreed that protest is important and is not something to be frowned upon. “Protesting is a reaction and a manifestation of grievances that have not been addressed, both in the community and institutions of higher learning,” Moema said. He added that it needs to be acknowledged that protesting is not a bad thing, and that it is “a democratic right enshrined in our Constitution”. 

These sentiments tied in with those of UFS Rector and Vice-Chancellor Prof Francis Petersen, who said that protesting campaigns like the #RhodesMustFall and subsequent #FeesMustFall movements addressed certain issues and were actually helping to resolve and address the issues at hand. “Some of these are not resolved, but the role protest plays is quite critical.” 

Management must ensure stakeholder safety

Prof Petersen aimed to contextualise student protests from the viewpoint of the university management team. He said the UFS is home to both students and staff, and management’s mandate is to ensure that everyone feels welcome and can reach their maximum potential in an enabling environment. “The formal structures must facilitate and ensure that staff and students do what they are here to do,” Prof Petersen said. 

“The question is how that protest is being conducted, as there are rules for protesting; in fact the Constitution tries to assist and guide us on how protest should be conducted,” Prof Petersen said. “Protesting is a constitutional right, and we respect that right at the UFS.”

Student equivalent of dialogue planned

The Division of Student Affairs plans to host a student equivalent of this dialogue in the second semester. “This discussion was to get the perspective from academics, and then we will get the student perspective,” Moema said.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept